Aligning the economic value of companion diagnostics and stratified medicines

Journal of Personalized Medicine

Volumn 2, Issue 4, 2012, Pages 257-266

  Blair, Edward D ^a   Stratton, Elyse K ^a   Kaufmann, Martina ^a  

^a Integrated Medicines Ltd   (United Kingdom)

Author keywords

Companion diagnostic; Economic value; Health outcomes; Multiple stakeholders; Regulation; Reimbursement; Stratified medicines

Indexed keywords

CRIZOTINIB; TRASTUZUMAB; VEMURAFENIB;

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG COST; DRUG INDUSTRY; ECONOMIC ASPECT; HEALTH CARE; HEALTH ECONOMICS; HUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REIMBURSEMENT; REVIEW; SOCIOECONOMICS; STRATIFIED MEDICINES;

EID: 85007249751     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm2040257     Document Type: Review

References (43)

1. Walker, I.; Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 2009, 8, 15-16.
2. Trusheim, M.R.; Berndt, E.R.; Douglas, F.L. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2007, 6, 287-293.
3. Blair, E.D. Predictive tests and personalised medicine. Drug Discov. World (Autumn) 2009, 22, 27-31.
4. Gilham, I. Theranostics: An emerging tool in drug discovery and commercialisation. Drug Discov. World (Autumn) 2002, 6, 24-32.
5. Trusheim, M.R.; Burgess, B.; Hu, S.X.; Long, T.; Averbuch, S.D.; Flynn, A.A.; Lieftucht, A.; Mazumder, A.; Milloy, J.; Shaw, P.M.; et al. Quantifying factors for the success of stratified medicine. Nat. Rev. Drug Discov. 2011, 10, 817-833.
6. Agarwal, A. Overlooked Opportunities. Available online: http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=574630&pageID=1&sk=&date (accessed on 20 August 2012).
7. Blair, E.D. Assessing the value-adding impact of diagnostic-type tests on drug development and marketing. Mol. Diagn. Ther. 2008, 12, 331-337.
8. Hughes, B. The comparative effectiveness challenge. Nat. Rev. Drug Discov. 2009, 8, 261-263.
9. Hughes, B. Novel risk-sharing scheme puts the spotlight on biomarkers. Nat. Rev. Drug Discov. 2007, 6, 945.
10. Blair, E.D.; Blakemore, J.A. Drug-diagnostic co-development: How to harness the value. Drug Discov. Today 2011, 16, 902-905.
11. Allen, D.; Alves, L.; Caruncho, G.; Chin, D.; Cohn, D.; Damle, B.; Dracos, B.; Friend, S.; Ha, J.; Kadar, A.; et al. The new science of personalized medicine. Available online: http://www.PWC.com (accessed on 20 August 2012).
12. Davis, J.C.; Furstenthal, L.; Desai, A.A.; Norris, T.; Sutaria, S.; Fleming, E.; Ma, P. The microeconomics of personalized medicine: Today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 2009, 8, 279-286.
13. Personalized Medicine Coalition. The Case for Personalized Medicine 3rd ed. Available online: http://www.personalizedmedicinecoalition.org/(accessed on 20 August 2012).
14. Espicom Healthcare Intelligence. The World Pharmaceutical Markets Fact Book 2011. Available online: http://www.marketresearch.com/Espicom-Healthcare-Intelligence-v1129/Pharmaceutical-Fact-Book-6485983/(accessed on 20 August 2012).
15. EAC Diagnostics Industry Study 2011. Available online: http://www.eacorp.com (accessed on 20 August 2012).
16. Blair, E.D. Molecular diagnostics and personalized medicine: Value-assessed opportunities for multiple stakeholders. Pers. Med. 2010, 7, 143-161.
17. Pfizer invests in Monogram. Available online: http://www.fiercebiotech.com/story/pfizer-to-invest-25m-in-monogram-biosciences/2006-05-08 (accessed on 20 August 2012).
18. Mansfield, E.; Leptak, C. Draft Guidance for Industry and FDA Staff-In Vitro Companion Diagnostic Devices. Available online: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm (accessed on 20 August 2012).
19. Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507-2516.
20. Goodman, M. Xalkori and the Art of Modern Drug Development. In Vivo, February 2012, Article No. 2012800030.
21. Food and Drug Administration. FY2011 Innovative Drug Approvals. Available online: http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm276385.htm (accessed on 20 August 2012).
22. European Medicines Agency. Qualification of novel methodologies for medicine development: Guidance to applicants. Available online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000319.jsp&mid=WC0b01ac0580022bb0 (accessed on 20 August 2012).
23. Stynen, D. Revision of Europe's IVD Directive 98/79/EC-Lessons and results from the Public Consultation document. IVD Technology, 20 July 2011.
24. Maverick, N.Y. My take on the Crizotinib/xalkori FDA approval. Available online: http://pharmastrategyblog.com/2011/08/my-take-on-the-crizotinibxalkori-fda-approval.html/(accessed on 20 August 2012).
25. Herper, M. Gene Test for Pfizer Cancer Drug to Cost $1,500 per Patient. Available online: http://www.forbes.com/sites/matthewherper/2011/08/29/gene-test-for-pfizer-cancer-drug-to-cost-1500-per-patient/(accessed on 20 August 2012).
26. Sauter, G.; Lee, J.A.; Slamon, D.J.; Press, M.F. Reply to V. Arena et al. J. Clin. Oncol. 2010, 28, e85-e88.
27. Crino, L.; Kim, D.; Riely, G.J.; Janne, P.A.; Blackhall, F.H.; Camidge, D.R.; Hirsh, V.; Mok, T.; Solomon, B.J.; Park, K.; et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol. 2011, 29 (Suppl.), Abstract 7514.
28. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Jänne, P.A.; Costa, D.B.; et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363, 1693-1703.
29. Camidge, D.R.; Bang, Y.; Kwak, E.L.; Shaw, A.T.; Iafrate, A.J.; Maki, R.G.; Solomon, B.J.; Ou, S.I.; Salgia, R.; Wilner, K.D.; et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF 02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2011, 29 (Suppl.), Abstract 2501.
30. Crystal, A.S.; Shaw, A.T. New Targets in Advanced NSCLC: EML4-ALK. Clin. Adv. Hematol. Oncol. 2011, 9, 313-331.
31. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics. Cancer J. Clin. 2010, 60, 277-300.
32. Taube, S.E.; Lively, T. Challenges in drug and biomarker co-development. Recent Results Cancer Res. 2012, 195, 229-239.
33. Cheng, S.; Koch, W.H.; Wu, L. Co-development of a companion diagnostic for targeted cancer therapy. Biotechnology 2012, 29, 682-688.
34. COSMIC Database. Available online: http://www.sanger.ac.uk/genetics/CGP/cosmic/(accessed on 20 August 2012).
35. Yervoy vs. Zelboraf: Melanoma Drugs Battle for Market Share. Available online: http://seekingalpha.com/article/744721-yervoy-vs-zelboraf-melanoma-drugs-battle-for-market-share (accessed on 20 August 2012).
36. Roche Half Year Results 2012. Available online: http://www.roche.com/investors/ir_agenda/halfyear-2012.htm (accessed on 20 August 2012).
37. Roche/Plexxikon: vemurafenib set to impact melanoma market. Available online: http://www. datamonitor.com/store/News/rocheplexxikon_vemurafenib_set_to_impact_melanoma_market? productid=9F516C6D-E974-47E4-8060-11C464770B05 (accessed on 20 August 2012).
38. Food and Drug Administration. FDA approves new treatment for a type of late-stage skin cancer. Available online: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm (accessed on 20 August 2012).
39. Uproar as NICE rejects B-MS skin cancer drug Yervoy. Available online: http://www. pharmatimes.com/article/11-10-14/Uproar_as_NICE_rejects_B-MS_skin_cancer_drug_Yervoy.aspx (accessed on 20 August 2012).
40. NICE consults on a new treatment for skin cancer. Available online: http://www.nice.org.uk/newsroom/pressreleases/VemurafenibForMelanomaACD.jsp (accessed on 20 August 2012).
41. Atherly, A.J.; Camidge, D.R. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer 2012, 106, 1100-1106.
42. Miller, I.A.; Ashton-Chess, J.; Spolders, H.; Fert, V.; Ferrara, J.; Kroll, W.; Askaa, J.; Larcier, P.; Terry, P.F.; Bruinvels, A.; et al. Market access challenges in the EU for high medical value diagnostic tests. Pers. Med. 2011, 8, 137-148.
43. Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (Arzneimittelmarktneuordnungsgesetz-AMNOG). Available online: http://www.bgbl.de/Xaver/start.xav?startbk=Bundesanzeiger_BGBl&bk=Bundesanzeiger_BGBl&start=//*[@attr_id=%27bgbl110s2262.pdf%27] (accessed on 20 August 2012).